Asset profile
vanzacaftor/tezacaftor/ivacaftor · Vertex Pharmaceuticals (VRTX)
- Indication
- cystic fibrosis
- Also known as
- ALYFTREK, elexacaftor/tezacaftor/ivacaftor and ivacaftor, TRIKAFTA, VNZ/TEZ/D-IVA
Company
VRTXVertex Pharmaceuticals
VRTXVertex PharmaceuticalsVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex …
On the calendar
Timeline
Newest first.
Oct 9, 2026
05:15 PM
VRTXVertex PharmaceuticalsVertex Presents ALYFTREK Pancreatic Function Recovery Data at NACFC
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT07108153 | Phase 2 | Completed | Jun 25, 2026 | 15 | 10 of 13 sites in the United States |
| NCT03506061 | Phase 2 | Completed | Feb 13, 2024 | 42 | 2 of 2 sites in the United States |
More from Vertex Pharmaceuticals
Other drugs and candidates from the same company tracked in this sector.